TheraRadar
← Back
Data updated: Mar 29, 2026

Hikma

Infectious DiseaseOncologyCardiovascular
Generics

Hikma is a generic drug manufacturer focused on Infectious Disease, Oncology, Cardiovascular. Key products include IMMPHENTIV.

1947
Since
460
Drugs
-
Trials
3478
Approved (2yr)

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Infectious Disease 24%
25 drugs
Oncology 23%
23 drugs Phase 2: 1 Phase 1: 1
Cardiovascular 22%
23 drugs
Dermatology 17%
18 drugs
Neurology 14%
14 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...